Shop by goal
Popular compounds
Research resources
Recently viewed
Retatrutide: Metabolic / Fat Loss research guide
In short: Retatrutide, research triple agonist of the GLP-1 / GIP / glucagon receptor system — among the largest body-composition changes reported in incretin-class research. It is studied in preclinical (cell and animal) research and is supplied strictly for laboratory use — not for human or clinical use.
Not medical advice. Retatrutide is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
Retatrutide at a glance
What Retatrutide is
Retatrutide is a triple receptor agonist of the GLP-1 / GIP / glucagon system, with the largest body-composition effects reported for any incretin-class peptide in published research.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Retatrutide, research triple agonist of the GLP-1 / GIP / glucagon receptor system — among the largest body-composition changes reported in incretin-class research.
Research contexts
Peer-reviewed literature typically discusses Retatrutide in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Typical study contexts
Why Metabolic / Fat Loss research matters
Metabolic peptides in this category are investigated for appetite signalling, incretin pathways, and energy balance in research models. Literature emphasises mechanisms rather than lifestyle advice.
Mechanisms (technical review)
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Lab handling & preparation
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 1–12 mg subcutaneously (dose escalation protocol) · Once weekly subcutaneous injection · Dose-proportional PK; t½ ≈ 6 days; Tmax = 12–72 h; hepatic metabolism without CYP interaction; dose escalation: 1 mg → 2 mg → 4 mg → 8 mg → 12 mg over 20–24 weeks in clinical protocols. Phase 3 TRIUMPH-1 (obesity) reported in 2025; further TRIUMPH readouts (type 2 diabetes, cardiovascular/kidney outcomes) expected through 2026.
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
Common Questions People Are Asking
What is retatrutide?
Retatrutide is an investigational triple agonist — it activates the GLP-1, GIP and glucagon receptors — developed by Eli Lilly and still in clinical trials (not approved anywhere). Retatrutide is the research-grade form of this retatrutide peptide, supplied as a lyophilised powder strictly for in-vitro and preclinical laboratory research. It is not an approved medicine and is not for human use.
What does retatrutide do?
In published research retatrutide activates three receptors at once — GLP-1 and GIP (satiety, insulin secretion, adipose effects) plus glucagon (hepatic energy expenditure and liver-fat clearance). The triple mechanism is what distinguishes it from dual (tirzepatide) and single (semaglutide) agonists. These are research findings for the molecule, not human-use guidance; Retatrutide is supplied for research only.
Is retatrutide FDA approved?
No. Retatrutide is still in clinical trials and is not approved by the FDA, EMA, or any other regulator. Retatrutide is an unapproved, research-grade lyophilised powder supplied for laboratory research use only — not for human consumption.
Is retatrutide safe?
Retatrutide is investigational; its safety is still being characterised in clinical trials and is not established for general use. Research-grade Retatrutide is not a sterile approved medicine and carries no human safety assurances. New-U supplies it for laboratory research only and makes no human-use or safety claims.
How much bacteriostatic water do you mix with 10 mg of retatrutide, and how is it reconstituted?
For laboratory preparation, concentration in mg/mL equals the vial mass in mg divided by the millilitres of diluent added — e.g. a 10 mg vial reconstituted with 1 mL of bacteriostatic water gives 10 mg/mL, or with 2 mL gives 5 mg/mL. Keep the reconstituted vial refrigerated at 1–6 °C and protected from light. This is preparation math only; New-U provides no human-use dosing guidance.
How is Retatrutide different from Tirzepatide or Semaglutide?
Semaglutide targets one receptor (GLP-1), Tirzepatide targets two (GLP-1 and GIP), and Retatrutide targets three (GLP-1, GIP, and glucagon). The glucagon arm is what drives the additional hepatic thermogenesis and liver-fat clearance that set Retatrutide apart in published research.
Why is the glucagon receptor useful here? Glucagon raises blood sugar, right?
It does, but at the right intensity and in combination with GLP-1, glucagon receptor agonism stimulates hepatic energy expenditure and fat oxidation without significant net glucose elevation. The GLP-1 arm offsets any glycemic downside while the glucagon arm delivers unique energy-balance effects.
Is Retatrutide an approved medicine?
No. Retatrutide is supplied for in-vitro and preclinical research only and is not approved as a medicine in any jurisdiction.
What is the typical research dose escalation?
Published research protocols use a step-up schedule from 1 mg weekly, doubling over several weeks to 2 mg, 4 mg, 8 mg, and ultimately 12 mg. The gradual escalation is designed to minimise GI signals as systems adapt to triple-receptor activation.
Retatrutide vs tirzepatide — which showed more weight loss in research?
In their respective obesity programmes the triple agonist reported larger mean reductions: retatrutide reached about 24.2% at 48 weeks in Phase 2 (NEJM 2023) and 28.3% at 80 weeks in Phase 3 TRIUMPH-1, while tirzepatide reported about 20.9% at 72 weeks in SURMOUNT-1. The difference is widely attributed to retatrutide's added glucagon-receptor arm, which raises energy expenditure on top of appetite suppression. These are cross-trial descriptive comparisons, not head-to-head results, and both compounds are supplied only as research-grade material for laboratory use, not for human use.
How is retatrutide reconstituted and stored?
Keep the lyophilised powder at −20 °C in the freezer. Reconstitute with bacteriostatic water directed down the vial wall and swirl gently rather than shaking; the in-solution concentration in mg/mL equals the vial mass divided by the millilitres of diluent added. Refrigerate the reconstituted vial at 1–6 °C, protect it from light, and avoid repeated freeze-thaw cycles, which can damage the C20 fatty-acid tail. This is laboratory-handling guidance only — not a human-use protocol.
What happens when you stop taking GLP-1s?
Across the published GLP-1 literature, withdrawal of a GLP-1 receptor agonist is consistently followed by the return of appetite and partial-to-substantial regain of lost weight, because the appetite and gastric-emptying effects depend on continued receptor activation. Retatrutide is a triple GIP/GLP-1/glucagon agonist still in clinical trials, so any such observations describe investigational or approved medicines in human studies. Retatrutide is an unapproved research-grade peptide supplied for laboratory research only and is not for human use.
Is this page medical advice? Can I use Retatrutide for my health?
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Where do I find Retatrutide specs, purity certificates and pricing?
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Related peptide guides
Other compounds researchers often read about alongside Retatrutide.
Scientific sources & further reading
Primary literature and registries for Retatrutide, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Ready to order? View full product specs
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: GGG Triple Agonist, GLP-1/GIP/Glucagon Receptor Triple Agonist, Tri-Agonist
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io